Welcome to our dedicated page for Centogene N.V. news (Ticker: CNTGF), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. stock.
Centogene N.V. (OTC: CNTGF) drives innovation in rare and neurodegenerative disease research through its integrated multiomic platform and global Biodatabank. This page provides official updates and press releases essential for understanding the company's progress in diagnostics, pharmaceutical collaborations, and data-driven healthcare solutions.
Access timely announcements including quarterly financial results, strategic partnership developments, regulatory milestones, and technological advancements like CentoCard® adoption. Investors and researchers will find curated updates on biomarker discoveries, clinical trial partnerships, and Centogene's contributions to precision medicine.
All content is sourced directly from company disclosures, ensuring reliability for making informed decisions. The resource emphasizes Centogene's unique position at the intersection of genetic research and therapeutic development, particularly through its diverse patient dataset covering 120 countries.
Bookmark this page for streamlined access to Centogene's latest corporate communications, including updates on its diagnostic services expansion and collaborations with leading pharmaceutical organizations. Check back regularly for insights into how CNTGF continues to shape the future of rare disease management.
Centogene N.V. (OTC: CNTGF) has completed the sale of its operating subsidiaries to Charme Capital Partners affiliate, as previously announced on November 13, 2024. The transaction includes the sale of 100% ownership in Centogene GmbH and certain intercompany receivables, along with the assumption of the Company's Oxford Finance loan.
Following shareholder approval at the December 4, 2024 Extraordinary General Meeting, Centogene N.V. and its remaining subsidiary, Centogene Switzerland AG, will cease operations. The company will proceed with the liquidation of Centogene Switzerland AG and enter dissolution in accordance with Dutch law. A liquidation distribution to shareholders is expected, with the exact amount dependent on running costs and necessary reserves for expenses and liabilities.
The Company's securities will no longer be quoted on the OTC market, and its reporting obligations under the U.S. Securities Exchange Act have been suspended.
CENTOGENE (OTC: CNTGF) announced the results of its Extraordinary General Meeting, where shareholders approved all proposed resolutions. The key highlight was the approval of the previously announced sale and transfer of Centogene GmbH to Charme Capital Partners , a pan-European private equity firm. The meeting had a representation of 57.16% of the Company's issued share capital.
CENTOGENE has announced a strategic sale of its operating subsidiaries to Charme Capital Partners for EUR 8.7 million. The transaction, expected to close in Q1 2025, includes a premium of up to 25% over the company's closing price. The deal involves funding from Saudi Arabian joint venture Lifera Omics and relief from Oxford Finance liabilities. Following the transaction, CENTOGENE N.V. plans to liquidate remaining subsidiaries, with shareholders expected to receive up to $0.20 per share in liquidation distribution. The company has secured approximately 57% shareholder support for the transaction, which requires majority approval at an upcoming Extraordinary General Meeting in December 2024.
CENTOGENE has published data from its Rostock International Parkinson's Disease (ROPAD) Study in The Lancet Neurology, supporting the association of a RAB32 gene mutation with Parkinson's disease (PD). The study analyzed Whole Genome Sequencing data from 3,354 PD patients, revealing that nine patients (0.3% of the cohort) carried the RAB32 c.213C>G mutation. This prevalence is significantly higher than the 0.002% found in general population databases.
Key findings include:
- The mutation's causal role in Parkinson's disease is supported
- Age at onset did not differ between mutation-positives and negatives
- Gender proportions and certain clinical characteristics differed
- The RAB32 Ser71Arg-associated haplotype supports a single founder mutational event
CENTOGENE has launched a ROPAD Consortium to continue driving PD research and treatment through collaborative efforts, aiming to streamline access to critical data and improve the potential for advancing treatment options.
FAQ
What is the current stock price of Centogene N.V. (CNTGF)?
What is the market cap of Centogene N.V. (CNTGF)?
